<DOC>
	<DOCNO>NCT02167945</DOCNO>
	<brief_summary>The purpose study evaluate Long-term Outcomes follow treatment ABT-450/r/ABT-267 , ABT-333 without RBV Adults With Genotype 1 Chronic Hepatitis C Virus ( HCV ) Infection</brief_summary>
	<brief_title>A Study Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 ( ABT-450/r/ABT-267 ) ABT-333 With Without Ribavirin ( RBV ) Adults With Genotype 1 Chronic Hepatitis C Virus ( HCV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>1 . Females must postmenopausal 2 year surgically sterile practice specific form birth control 2 . Chronic hepatitis C , genotype 1infection ( HCV RNA level great 1,000 IU/mL screen ) 3 . HCV genotype 1 infection per screen laboratory result 1 . Use contraindicate medication within 2 week dose 2 . Abnormal laboratory test 3 . Positive hepatitis B surface antigen antiHuman Immunodeficiency Virus Antibody 4 . Clinical history liver decompensation 5 . Presence hepatocellular carcinoma screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Na√Øve</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Non responder</keyword>
	<keyword>Relapser</keyword>
	<keyword>Null responder</keyword>
	<keyword>Treatment-Experienced</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Hepatitis C Genotype 1</keyword>
	<keyword>Compensated Cirrhosis</keyword>
	<keyword>Hepatitis C Virus</keyword>
</DOC>